TP53 and cancer: Tumor suppressor genes are difficult to target by conventional drug modalities and are commonly regarded as “undruggable.” Deniger et al. found that some neoantigens derived from hotspot mutations in TP53 (p.Y220C and p.G245S) had strong immunogenicity, and the transfer of TP53 “hotspot” mutation-reactive T cell receptors into peripheral blood T cells could be evaluated as a potential therapy for various cancer types [24, 25].